Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer

NCT02923180 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

33

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Enoblituzumab

Sponsor

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Collaborators

[object Object]